Integra LifeSciences vs ICU Medical
IART and ICUI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IART and ICUI compare
ICU Medical is the larger company, worth 3.9 times as much as Integra LifeSciences ($4.5B against $1.1B).
On earnings, ICU Medical is cheaper: it trades at 74.0× trailing earnings, against 86.9× for Integra LifeSciences.
Integra LifeSciences grew revenue faster over the last twelve months (0.84% versus −5.9% for ICU Medical).
ICU Medical keeps more of each dollar of sales as profit, with a net margin of 2.8% compared with 0.79% at Integra LifeSciences.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IART | ICUI |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $4.5B |
| Share price | $14.77 | $178.26 |
| Change, 1 year | 21.3% | 28.0% |
| Change, 5 years | −78.5% | −27.8% |
| Beta (5Y) | 1.25 | 1.00 |
| Employees | 3,700 | 13K |
| StockData Score | ||
| Total score | 9 | 9 |
| Valuation score | 3 (better) | 2 |
| Growth score | 2 | 2 |
| Performance score | 3 | 3 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 86.9× | 74.0× (better) |
| P/S | 0.7× (better) | 2.0× |
| P/B | 1.1× (better) | 2.0× |
| EV/EBITDA | 11.5× (better) | 17.1× |
| P/FCF | 13.4× (better) | 21.4× |
| FCF yield | 7.5% (better) | 4.7% |
| Fair value | $14.84 | $134.86 |
| Margin of safety | 0.47% (better) | −32.2% |
| Growth | ||
| Revenue growth (TTM) | 0.84% (better) | −5.9% |
| Revenue growth, 5Y average | 3.6% | 11.9% (better) |
| EPS growth, 5Y average | – | −62.5% |
| Profitability | ||
| Gross margin | 52.4% (better) | 40.3% |
| Operating margin | 4.4% | 5.1% (better) |
| Net margin | 0.79% | 2.8% (better) |
| FCF margin | 5.2% | 9.6% (better) |
| Return on equity | 1.2% | 2.8% (better) |
| Return on invested capital | 5.6% (better) | 3.6% |
| Financial health | ||
| Debt / equity | – | 0.53 |
| Net debt / EBITDA | – | 2.74 |
| Interest coverage | 0.8× | 1.4× (better) |
| Current ratio | 3.62 (better) | 2.37 |
| Altman Z-score | 1.29 | 2.66 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 94.4% | 104% |
| Held by insiders | 3.4% | 1.8% |
| Insider net buying, 12 months | $0 (better) | −$7.5M |
| Short interest, % of float | 10.5% | 6.8% |
Go deeper
- IART stock overview
- IART income statement
- IART valuation and score
- ICUI stock overview
- ICUI income statement
- ICUI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.